Compare Cassava Sciences Inc (FLNA) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Kraft Heinz Co — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Kraft Heinz Co trades at $22.44 (market cap $26.66B). The key difference: Kraft Heinz Co is far larger — about 676.6× Cassava Sciences Inc's market cap, and Kraft Heinz Co pays a 7.12% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Kraft Heinz Co for 129 Days on average.
| FLNA | KHC | |
|---|---|---|
Market Cap | $39.40M | $26.66B |
Volume | 759,018 | 31,300,109 |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $27.62 |
52-Week Low | $0.68 | $21.21 |
Typical Hold Time | 37 Days | 129 Days |
Enterprise Value | -$43.28M | $42.98B |
Dividend Yield | — | 7.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Kraft Heinz (KHC) trades at $21.98, down 0.23% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings have beaten estimates, but 2025 saw a net loss of $5.85 billion due to impairment charges, though operating cash flow remains strong at $4.46 billion. The company is executing a turnaround strategy, including a $700 million reinvestment and new product launches like Philadelphia cream cheese flavors, to revive brand relevance amid volume challenges.
The stock offers a discounted valuation with a P/E of 13.04 and P/B of 0.72, but high debt and negative ROE pose risks. Analyst consensus is cautious with a hold-heavy rating and $23.78 price target, implying modest upside. Key opportunities include cash flow stability and brand reinvestment, while risks involve persistent volume declines and competitive pressures in the consumer goods sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
